STAGE IV BLADDER CANCER AJCC V8
Clinical trials for STAGE IV BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to boost immune attack on bladder cancer
Disease control OngoingThis early-phase study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. Tazemetostat blocks certain enzymes that help cancer grow, while pembrolizumab helps the immune system fight the cancer. The goal is to f…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:59 UTC
-
New hope for bladder cancer patients who Can't take standard chemo
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread or come back. The trial includes 72 adults whose cancer cannot be treated with the standar…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:58 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:54 UTC
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 13:52 UTC
-
Immunotherapy plus chemo shows promise against Tough-to-Treat cancers
Disease control OngoingThis early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo aims to stall advanced bladder cancer
Disease control OngoingThis study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo aims to extend life in tough bladder cancer cases
Disease control OngoingThis study tests whether adding the drug eribulin to standard chemotherapy helps people with advanced bladder cancer live longer. It includes 184 adults whose cancer has spread and no longer responds to immunotherapy. The goal is to see if the new combination works better than us…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for bladder cancer patients who can't take chemo: radiation plus immunotherapy combo tested
Disease control OngoingThis study tests whether combining radiation therapy with two immunotherapy drugs (durvalumab with or without tremelimumab) can help control advanced bladder cancer in people who cannot or will not have chemotherapy. About 13 participants with cancer that has spread or can't be s…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for tough bladder cancers: drug targets DNA repair flaws
Disease control TerminatedThis study tests a drug called olaparib in people with advanced bladder or other genitourinary cancers that have specific DNA-repair defects. Olaparib works by blocking a protein that cancer cells need to repair their damaged DNA, which may stop the cancer from growing. The trial…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Could a common heart pill boost cancer immunotherapy?
Disease control OngoingThis study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New drug combo shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. …
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Can a gene test tell who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…
Matched conditions: STAGE IV BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 13:59 UTC